Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Matrix Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$2,832,791

163 payments

Through program year 2025, Matrix Clinical Research is reported as receiving $2,832,791 in research payments, across 163 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $241,135 17
2024 Research $148,825 4
2023 Research $1,360,470 50
2022 Research $831,915 20
2021 Research $70,199 33
2020 Research $153,924 36
2019 Research $26,323 3

Breakdown

Who paid Research payments · program years 2019–2025
  1. Bavarian Nordic A/S $2,127,476 60 payments
  2. Becton, Dickinson and Company $155,005 2 payments
  3. Sekisui Diagnostics LLC $132,825 1 payment
  4. GlaxoSmithKline, LLC. $94,996 28 payments
  5. Roche Molecular Systems, Inc. $89,630 16 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $64,252 8 payments
  7. Padagis US LLC $41,350 3 payments
  8. Organon LLC $39,794 26 payments
  9. Celgene Corporation $30,000 6 payments
  10. Pfizer Inc. $24,712 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age $1,340,303 46 payments
  2. Nct05238025 $787,173 14 payments
  3. SARS CoV-2 $155,005 2 payments
  4. A Multicenter Study to Evaluate the Performance of the OSOM COVID-19 Antigen Rapid Test and Acucy SARS-CoV-2 Antigen Test in Point of Care Locations $132,825 1 payment
  5. RSV Mat-004 $94,996 28 payments
  6. Rd006770 $89,630 16 payments
  7. BAY1454032 Essure System for Permanent Birth Control $64,252 8 payments
  8. Multi-Center, Randomized, Double-Masked, Active Controlled, Parallel Group Study to Compare Perrigo's Brinzolamide Brimonidine Ophthalmic Suspension 1 percent to Simbrinza in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes $41,350 3 payments
  9. 8415-8415-060-PN060-Extended Duration Study (Celanese + 2 years)-Contraception-SC-imp-Supplemental Registration-USA-LD-B $38,746 1 payment
  10. A Phase 1 Openlabel Study to Evaluate the Pharmacokinetics Safety and Tolerability of Orally Administered Nirmatrelvirritonavir in Pregnant Women With Mildtomoderate Covid19 $19,658 3 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $39,794 26 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record